OSE IMMUNO (OSE.PA) Stock Fundamental Analysis
EPA:OSE - Euronext Paris - Matif - FR0012127173 - Common Stock - Currency: EUR
Taking everything into account, OSE scores 5 out of 10 in our fundamental rating. OSE was compared to 68 industry peers in the Biotechnology industry. OSE has an excellent financial health rating, but there are some minor concerns on its profitability. OSE is valued quite cheap, while showing a decent growth score. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year OSE was profitable.
OSE had a positive operating cash flow in the past year.
OSE had negative earnings in 4 of the past 5 years.
OSE had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
OSE has a Return On Assets of 30.21%. This is amongst the best in the industry. OSE outperforms 98.53% of its industry peers.
OSE has a better Return On Equity (58.68%) than 97.06% of its industry peers.
With an excellent Return On Invested Capital value of 30.99%, OSE belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.21% | ||
| ROE | 58.68% | ||
| ROIC | 30.99% |
ROA(3y)-5.73%
ROA(5y)-10.16%
ROE(3y)-31.94%
ROE(5y)-31.6%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
OSE has a better Profit Margin (44.88%) than 95.59% of its industry peers.
OSE has a Operating Margin of 52.42%. This is amongst the best in the industry. OSE outperforms 98.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 52.42% | ||
| PM (TTM) | 44.88% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), OSE is creating value.
OSE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, OSE has more shares outstanding
The debt/assets ratio for OSE has been reduced compared to a year ago.
2.2 Solvency
OSE has an Altman-Z score of 3.28. This indicates that OSE is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of OSE (3.28) is better than 76.47% of its industry peers.
The Debt to FCF ratio of OSE is 0.95, which is an excellent value as it means it would take OSE, only 0.95 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.95, OSE belongs to the top of the industry, outperforming 97.06% of the companies in the same industry.
A Debt/Equity ratio of 0.60 indicates that OSE is somewhat dependend on debt financing.
OSE has a Debt to Equity ratio (0.60) which is in line with its industry peers.
Even though the debt/equity ratio score it not favorable for OSE, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | 0.95 | ||
| Altman-Z | 3.28 |
ROIC/WACC4.28
WACC7.24%
2.3 Liquidity
OSE has a Current Ratio of 3.46. This indicates that OSE is financially healthy and has no problem in meeting its short term obligations.
OSE's Current ratio of 3.46 is fine compared to the rest of the industry. OSE outperforms 67.65% of its industry peers.
OSE has a Quick Ratio of 3.46. This indicates that OSE is financially healthy and has no problem in meeting its short term obligations.
OSE's Quick ratio of 3.46 is fine compared to the rest of the industry. OSE outperforms 69.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.46 | ||
| Quick Ratio | 3.46 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 245.42% over the past year.
Looking at the last year, OSE shows a very strong growth in Revenue. The Revenue has grown by 3646.52%.
Measured over the past years, OSE shows a very strong growth in Revenue. The Revenue has been growing by 26.31% on average per year.
EPS 1Y (TTM)245.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.06%
Revenue 1Y (TTM)3646.52%
Revenue growth 3Y46.93%
Revenue growth 5Y26.31%
Sales Q2Q%-0.81%
3.2 Future
Based on estimates for the next years, OSE will show a very negative growth in Earnings Per Share. The EPS will decrease by -57.77% on average per year.
The Revenue is expected to decrease by -28.54% on average over the next years. This is quite bad
EPS Next Y-82.85%
EPS Next 2Y-63.7%
EPS Next 3Y-57.77%
EPS Next 5YN/A
Revenue Next Year-47.32%
Revenue Next 2Y-20.24%
Revenue Next 3Y-28.54%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 2.96, the valuation of OSE can be described as very cheap.
98.53% of the companies in the same industry are more expensive than OSE, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of OSE to the average of the S&P500 Index (27.41), we can say OSE is valued rather cheaply.
A Price/Forward Earnings ratio of 12.22 indicates a correct valuation of OSE.
OSE's Price/Forward Earnings ratio is rather cheap when compared to the industry. OSE is cheaper than 95.59% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of OSE to the average of the S&P500 Index (35.19), we can say OSE is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2.96 | ||
| Fwd PE | 12.22 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of OSE indicates a rather cheap valuation: OSE is cheaper than 100.00% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of OSE indicates a rather cheap valuation: OSE is cheaper than 100.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.4 | ||
| EV/EBITDA | 1.29 |
4.3 Compensation for Growth
OSE's earnings are expected to decrease with -57.77% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-63.7%
EPS Next 3Y-57.77%
5. Dividend
5.1 Amount
OSE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:OSE (7/14/2025, 9:51:32 AM)
5.06
-0.01 (-0.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners3.11%
Inst Owner ChangeN/A
Ins Owners24.93%
Ins Owner ChangeN/A
Market Cap115.92M
Analysts82.22
Price Target16.83 (232.61%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-44.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2.96 | ||
| Fwd PE | 12.22 | ||
| P/S | 1.39 | ||
| P/FCF | 2.4 | ||
| P/OCF | 2.39 | ||
| P/B | 1.82 | ||
| P/tB | 5.85 | ||
| EV/EBITDA | 1.29 |
EPS(TTM)1.71
EY33.79%
EPS(NY)0.41
Fwd EY8.18%
FCF(TTM)2.11
FCFY41.72%
OCF(TTM)2.11
OCFY41.79%
SpS3.64
BVpS2.79
TBVpS0.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.21% | ||
| ROE | 58.68% | ||
| ROCE | 42.16% | ||
| ROIC | 30.99% | ||
| ROICexc | 72.04% | ||
| ROICexgc | 5261.08% | ||
| OM | 52.42% | ||
| PM (TTM) | 44.88% | ||
| GM | N/A | ||
| FCFM | 57.96% |
ROA(3y)-5.73%
ROA(5y)-10.16%
ROE(3y)-31.94%
ROE(5y)-31.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | 0.95 | ||
| Debt/EBITDA | 0.81 | ||
| Cap/Depr | 2.33% | ||
| Cap/Sales | 0.09% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 102.97% | ||
| Profit Quality | 129.16% | ||
| Current Ratio | 3.46 | ||
| Quick Ratio | 3.46 | ||
| Altman-Z | 3.28 |
F-Score8
WACC7.24%
ROIC/WACC4.28
Cap/Depr(3y)5.62%
Cap/Depr(5y)12.68%
Cap/Sales(3y)4%
Cap/Sales(5y)3.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)245.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.06%
EPS Next Y-82.85%
EPS Next 2Y-63.7%
EPS Next 3Y-57.77%
EPS Next 5YN/A
Revenue 1Y (TTM)3646.52%
Revenue growth 3Y46.93%
Revenue growth 5Y26.31%
Sales Q2Q%-0.81%
Revenue Next Year-47.32%
Revenue Next 2Y-20.24%
Revenue Next 3Y-28.54%
Revenue Next 5YN/A
EBIT growth 1Y287.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-72.82%
EBIT Next 3Y-64.61%
EBIT Next 5YN/A
FCF growth 1Y341.85%
FCF growth 3YN/A
FCF growth 5Y40.61%
OCF growth 1Y345.08%
OCF growth 3YN/A
OCF growth 5Y39.6%